Cargando…

Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the most common reasons of enzyme increase in liver. In About 10 percent of patients with NAFLD, the disease progresses toward Non Alcoholic Steatohepatitis (NASH) and about one third of them may progress toward cirrhosis, liver dysfunct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajiaghamohammadi, Ali Akbar, Ziaee, Amir, Oveisi, Sonia, Masroor, Homa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475019/ https://www.ncbi.nlm.nih.gov/pubmed/23087748 http://dx.doi.org/10.5812/hepatmon.6099

Ejemplares similares

To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori
por: Hajiaghamohammadi, Ali Akbar, et al.
Publicado: (2016)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Silymarin’s Protective Effects and Possible Mechanisms on Alcoholic Fatty Liver for Rats
por: Zhang, Wei, et al.
Publicado: (2013)

The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease
por: Bechynska, Kamila, et al.
Publicado: (2021)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report
por: Chantarojanasiri, Tanyaporn
Publicado: (2023)

Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
por: Liu, Jieying, et al.
Publicado: (2023)

The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial
por: Razavizade, Mohsen, et al.
Publicado: (2013)

Effect of Silymarin and Quercetin in a Miniaturized Scaffold in Wistar Rats against Non-alcoholic Fatty Liver Disease
por: Stephen Robert, Jaisheela Marry, et al.
Publicado: (2021)

Simultaneous Estimation of Metformin and Pioglitazone by Ultraviolet Spectrophotometry
por: Goswami, Laxmi, et al.
Publicado: (2010)

Efficacy of silymarin in patients with non-alcoholic fatty liver disease — the Siliver trial: a study protocol for a randomized controlled clinical trial
por: de Avelar, Camila Ribeiro, et al.
Publicado: (2023)

The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model
por: Hüttl, Martina, et al.
Publicado: (2021)

Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
por: Mazhar, Iqra J, et al.
Publicado: (2023)

Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial
por: Sayadishahraki, Masoud, et al.
Publicado: (2023)

Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
por: Marjani, Majid, et al.
Publicado: (2019)

Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients: A randomized double-blind clinical trial
por: Atarodi, Hamed, et al.
Publicado: (2022)

Criteria to Assess a Randomized Controlled Pilot Study: Response to Letter
por: Oveisi, Sonia
Publicado: (2013)

Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
por: Hashem, Ahmed
Publicado: (2023)

A Comparison of Health-Related Quality of Life among Normal-Weight, Overweight and Obese Adults in Qazvin Metabolic Diseases Study (QMDS), Iran: Health-Related Quality of Life among Obese Adults
por: Ghorbani, Azam, et al.
Publicado: (2013)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Formulation and Evaluation of Multilayered Tablets of Pioglitazone Hydrochloride and Metformin Hydrochloride
por: Chowdary, Y. Ankamma, et al.
Publicado: (2014)

Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials
por: Wang, Zeyu, et al.
Publicado: (2023)

Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
por: Kaur, Simran, et al.
Publicado: (2023)

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)
por: Ozaki, Anna, et al.
Publicado: (2019)

Association between Metabolic Syndrome and Premicroalbuminuria among Iranian Women with Polycystic Ovary Syndrome: A Case Control Study: Met Syn. and Premicroalbuminuria in PCOS
por: Ziaee, Amir, et al.
Publicado: (2013)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
por: Shahebrahimi, Karoon, et al.
Publicado: (2016)

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
por: Lee, Yeong Yeh, et al.
Publicado: (2023)

Hepatoprotective Property of Oral Silymarin is Comparable to N-Acetyl Cysteine in Acetaminophen Poisoning
por: Kazemifar, Amir Mohammad, et al.
Publicado: (2012)

Investigating the impact of silymarin on liver oxidative injury
por: Jamalian, Mohammad, et al.
Publicado: (2020)

Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: improvement of lipid metabolism
por: Veleba, Jiri, et al.
Publicado: (2015)

Silymarin Dehydroflavonolignans Chelate Zinc and Partially Inhibit Alcohol Dehydrogenase
por: Tvrdý, Václav, et al.
Publicado: (2021)

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
por: Ahn, Hwa Young, et al.
Publicado: (2018)

Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes
por: Kamolvisit, Sarunporn, et al.
Publicado: (2021)

Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats
por: Mengesha, Tewodros, et al.
Publicado: (2021)

HbA(1C) as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters
por: Masroor, Muhammad, et al.
Publicado: (2021)

Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes
por: Esteghamati, Alireza, et al.
Publicado: (2013)

Effect of silymarin and metformin on the sperm parameters and histopathological changes of testes in diabetic rats: An experimental study
por: Pourheydar, Bagher, et al.
Publicado: (2022)

Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2017)

Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
por: Jianfang, Fu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vsgb7jmu62mjjq571d1o66c7cj